Debt-to-equity of Milestone Pharmaceuticals Inc. from 30 Sep 2019 to 30 Sep 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Milestone Pharmaceuticals Inc. quarterly Debt-to-equity in % history and change rate from 30 Sep 2019 to 30 Sep 2025.
  • Milestone Pharmaceuticals Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was 2687%, a 1214% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Milestone Pharmaceuticals Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 2687% +2482% +1214% 30 Sep 2025
Q2 2025 1913% +1716% +873% 30 Jun 2025
Q1 2025 391% +208% +114% 31 Mar 2025
Q4 2024 215% +50% +30% 31 Dec 2024
Q3 2024 205% +109% +114% 30 Sep 2024
Q2 2024 197% +142% +258% 30 Jun 2024
Q1 2024 183% +155% +562% 31 Mar 2024
Q4 2023 165% +157% +1970% 31 Dec 2023
Q3 2023 95% +89% +1309% 30 Sep 2023
Q2 2023 55% +49% +907% 30 Jun 2023
Q1 2023 28% +23% +441% 31 Mar 2023
Q4 2022 8% +3% +57% 31 Dec 2022
Q3 2022 7% +2% +44% 30 Sep 2022
Q2 2022 5% 0% +9.2% 30 Jun 2022
Q1 2022 5% 0% -5% 31 Mar 2022
Q4 2021 5% 0% -8.8% 31 Dec 2021
Q3 2021 5% -2% -26% 30 Sep 2021
Q2 2021 5% -1% -23% 30 Jun 2021
Q1 2021 5% -1% -10% 31 Mar 2021
Q4 2020 6% -1% -8.4% 31 Dec 2020
Q3 2020 6% +1% +14% 30 Sep 2020
Q2 2020 6% 30 Jun 2020
Q1 2020 6% 31 Mar 2020
Q4 2019 6% 31 Dec 2019
Q3 2019 6% 30 Sep 2019
* An asterisk sign (*) next to the value indicates that the value is likely invalid.